Rhythm Pharmaceuticals, Inc.
RYTM
Clasificación en acciones
#3066
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Precio por acción
$86.36
Última sincronización: 2026-10-16
Capitalización bursátil
$5.95B
Cambio (1 día)
-1.83%
Cambio (1 año)
-21.69%
País
US
Comercio Rhythm Pharmaceuticals, Inc. (RYTM)
Categoría
Healthcare
Margen Operativo de Rhythm Pharmaceuticals, Inc. (RYTM)
Margen Operativo al October 2026 TTM: -83.62%
Según los informes financieros más recientes y el precio de las acciones de Rhythm Pharmaceuticals, Inc., el margen operativo actual (TTM) es -83.62%. Al final de 2023, el margen operativo era -238.10%.
Historial de Margen Operativo de Rhythm Pharmaceuticals, Inc. desde 2012 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | -83.62% | -59.02% |
| 2024 | -204.04% | -14.30% |
| 2023 | -238.10% | -68.59% |
| 2022 | -757.92% | -85.94% |
| 2021 | -5,391.85% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 38.59% | -100.46% |
US
|
|
| -149.01% | -98.22% |
US
|
|
| 25.57% | -100.31% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.34% |
NL
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.